Preparation, characterization and in-vitro efficacy of quercetin loaded liquid crystalline nanoparticles for the treatment of asthma

Cherk Yong, DO; Saker, SR; Wadhwa, R; Chellappan, DK; Madheswaran, T; Panneerselvam, J; Tambuwala, MM; Bakshi, HA; Kumar, P; Pillay, V; Gupta, G; Oliver, BG; Wark, P; Hsu, A; Hansbro, PM; Dua, K; Zeeshan, F

Preparation, characterization and in-vitro efficacy of quercetin loaded liquid crystalline nanoparticles for the treatment of asthma

Cherk Yong, DO Saker, SR Wadhwa, R Chellappan, DK Madheswaran, T Panneerselvam, J Tambuwala, MM Bakshi, HA Kumar, P Pillay, V Gupta, G Oliver, BG

Wark, P Hsu, A Hansbro, PM

Dua, K

Zeeshan, F

Permalink

Publication Type:: Journal Article
Citation:: Journal of Drug Delivery Science and Technology, 2019, 54
Issue Date:: 2019-12-01

Closed Access

	Filename	Description	Size
	1-s2.0-S1773224719313383-main.pdf	Published Version	1.28 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Cherk Yong, DO	en_US
dc.contributor.author	Saker, SR	en_US
dc.contributor.author	Wadhwa, R	en_US
dc.contributor.author	Chellappan, DK	en_US
dc.contributor.author	Madheswaran, T	en_US
dc.contributor.author	Panneerselvam, J	en_US
dc.contributor.author	Tambuwala, MM	en_US
dc.contributor.author	Bakshi, HA	en_US
dc.contributor.author	Kumar, P	en_US
dc.contributor.author	Pillay, V	en_US
dc.contributor.author	Gupta, G	en_US
dc.contributor.author	Oliver, BG https://orcid.org/0000-0002-7122-9262	en_US
dc.contributor.author	Wark, P	en_US
dc.contributor.author	Hsu, A	en_US
dc.contributor.author	Hansbro, PM https://orcid.org/0000-0002-4741-3035	en_US
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159	en_US
dc.contributor.author	Zeeshan, F	en_US
dc.date.issued	2019-12-01	en_US
dc.identifier.citation	Journal of Drug Delivery Science and Technology, 2019, 54	en_US
dc.identifier.issn	1773-2247	en_US
dc.identifier.uri	http://hdl.handle.net/10453/137300
dc.description.abstract	© 2019 Elsevier B.V. The present study aims to formulate quercetin loaded liquid crystalline nanoparticles (LCN) and surface modified liquid crystalline nanoparticles (sm-LCN) as well as investigate their anti-inflammatory activity in human primary bronchial epithelial cell line (BCi-NS1.1) induced with lipopolysaccharide (LPS). Quercetin LCN were prepared using ultrasonication method. The formulated LCNs and sm-LCNs were characterised in terms of particle size, zeta potential as well as the drug encapsulation efficiency. Furthermore, their morphology and in vitro release profile were also studied. In addition, the anti-inflammatory activity of quercetin LCN and sm-LCNs were evaluated by measuring the concentration of pro-inflammatory markers namely interleukin (IL)-1β, IL-6 and IL-8 in BCI-NS1.1 cell lines via cytometric bead array. The molecular mechanism inherent to the inclusion of quercetin into monoolein nanosystem and surface modification of the nanosystem with chitosan was elucidated via molecular mechanics simulations. Quercetin LCN and sm-LCN significantly (p < 0.05) decreased the production of IL-1β, IL-6 and IL-8 compared to LPS only group. Encapsulation of quercetin into LCN and sm-LCN further enhanced its anti-inflammatory activity compared to quercetin in dimethyl sulfoxide (DMSO). In addition to that, quercetin LCN and sm-LCN also exhibited comparable activity to fluticasone in terms of significantly (p < 0.05) reducing the production of IL-1β and IL-6. Quercetin loaded LCN and sm-LCN could be a potential therapeutic intervention for asthma as they are efficacious in suppressing the production of key pro-inflammatory cytokines associated with the development of asthma.	en_US
dc.relation.ispartof	Journal of Drug Delivery Science and Technology	en_US
dc.relation.isbasedon	10.1016/j.jddst.2019.101297	en_US
dc.subject.classification	Pharmacology & Pharmacy	en_US
dc.title	Preparation, characterization and in-vitro efficacy of quercetin loaded liquid crystalline nanoparticles for the treatment of asthma	en_US
dc.type	Journal Article
utslib.citation.volume	54	en_US
utslib.for	1102 Cardiorespiratory Medicine and Haematology	en_US
utslib.for	1115 Pharmacology and Pharmaceutical Sciences	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
pubs.organisational-group	/University of Technology Sydney/Students
utslib.copyright.status	closed_access
pubs.publication-status	Published	en_US
pubs.volume	54	en_US

Abstract:

© 2019 Elsevier B.V. The present study aims to formulate quercetin loaded liquid crystalline nanoparticles (LCN) and surface modified liquid crystalline nanoparticles (sm-LCN) as well as investigate their anti-inflammatory activity in human primary bronchial epithelial cell line (BCi-NS1.1) induced with lipopolysaccharide (LPS). Quercetin LCN were prepared using ultrasonication method. The formulated LCNs and sm-LCNs were characterised in terms of particle size, zeta potential as well as the drug encapsulation efficiency. Furthermore, their morphology and in vitro release profile were also studied. In addition, the anti-inflammatory activity of quercetin LCN and sm-LCNs were evaluated by measuring the concentration of pro-inflammatory markers namely interleukin (IL)-1β, IL-6 and IL-8 in BCI-NS1.1 cell lines via cytometric bead array. The molecular mechanism inherent to the inclusion of quercetin into monoolein nanosystem and surface modification of the nanosystem with chitosan was elucidated via molecular mechanics simulations. Quercetin LCN and sm-LCN significantly (p < 0.05) decreased the production of IL-1β, IL-6 and IL-8 compared to LPS only group. Encapsulation of quercetin into LCN and sm-LCN further enhanced its anti-inflammatory activity compared to quercetin in dimethyl sulfoxide (DMSO). In addition to that, quercetin LCN and sm-LCN also exhibited comparable activity to fluticasone in terms of significantly (p < 0.05) reducing the production of IL-1β and IL-6. Quercetin loaded LCN and sm-LCN could be a potential therapeutic intervention for asthma as they are efficacious in suppressing the production of key pro-inflammatory cytokines associated with the development of asthma.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/137300